Aspira Women’s Health Partners with Dorsata to Create New Clinical Workflow Tool for Adnexal Masses Page 1

The innovative new tool will be made available for integration into electronic health records at more than 300 clinical sites, serving 2,500 clinical users

AUSTIN, Texas, Aug. 27, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a women’s health bioanalytical company focused on developing diagnostic tools for gynecological conditions, today signed a definitive agreement with Dorsata, a healthcare software company, to create a protocol workflow tool for the clinical management of adnexal masses.